Macrophages are induced by LPS to release a number of products that determine the host response during gram negative sepsis. To examine the role of one such substance, tumor necrosis factor (TNF), in mediating LPS-induced injury, we employed a rabbit model of endotoxic shock to (a) determine the kinetics and extent of release of TNF into plasma after injection of LPS, and (b) to evaluate the protective effect of in vivo neutralization of LPS-induced TNF by prior infusion of anti-TNF antibody. TNF was maximally induced 45-100 min after injection of 10 jig i.v. parent Salmonella Minnesota Re595 LPS or 250 ;&g Re595 LPS-HDL complexes. Maximal induction of TNF by LPS was associated with development of hypotension, focal hepatic necrosis, intravascular fibrin deposition and lethality. Based on (a) the peak levels of TNF observed in serum, 2.5 X 103 U/mIl, (b) the specific activity of purified rabbit macrophage-derived TNF, 1 X 108 U/mg, and (c) the biphasic disappearance of intravenously injected purified TNF (t1/2 = 0.5 min. 11 min) we constructed a kinetic model showing that at least 130 jig of TNF (1.3 X 107 U) was released into plasma 30-200 min postinjection of LPS. Prior infusion. of anti-TNF antibody (3045 min before LPS injection) resulted in neutralization of the LPS-induced serum TNF activity and provided significant protection from the development of hypotension, fibrin deposition, and lethality. Thus, these results provide further evidence that TNF plays a central role mediating the pathophysiologic changes that occur during gram negative endotoxic shock.
Introduction
Complications of gram negative sepsis include hypotension, fever, metabolic acidosis, disseminated intravascular coagulation (DIC),' and death. The search for the toxic principal of 1 . Abbreviations used in this paper: CT, core temperature; HrTNF, human recombinant TNF; LPS-HDL, Re595 lipopolysaccharide-high density lipoprotein complexes; MAP, mean arterial pressure; P. acnes, Propionibacterium acnes; PA-LPS, plasma-altered LPS formed by exposure ofparent Re595 LPS to serum; Parent LPS, lipopolysaccharide extracted from Salmonella Minnesota Re595; PEM, peritoneal exudate macrophages obtained from mineral oil-treated rabbits; PEM-TNF, tumor necrosis factor derived from rabbit PEM; TNF, tumor necrosis factor. gram negative bacteria led to the discovery that gram negative culture filtrates, extracted endotoxin (protein-LPS), purified LPS, and lipid A induce pathophysiologic changes characteristic of septic shock when injected into humans or experimental animals (1) (2) (3) (4) . Recent studies have focused on interactions of LPS with formed blood elements, plasma proteins and tissue-fixed cells in order to better understand the molecular mechanisms that lead to LPS-induced injury (1) . For example, LPS has been shown to interact with a number of plasma constituents including complement proteins, coagulation factors, HDL and a newly recognized acute phase reactant (1, (5) (6) (7) . Analysis of LPS interactions with cells demonstrated the importance of macrophages as primary targets for LPS when the in vivo tissue distribution of radiolabeled LPS was analyzed at the cellular level (8) .
The central role of macrophages in mediating the host response to LPS has been suggested by a number ofexperiments such as the studies of Glode et al. showing that reconstitution of irradiated C3H/HeJ (LPS-nonresponsive) mice with spleen cells from C3H/HeN (LPS-responsive) mice rendered the HeJ mice responsive to LPS (9) . More recently Galanos et al. have shown that transfer of bone marrow-derived macrophages from C3H/HeN mice to irradiated C3H/HeJ mice results in reconstitution of the LPS-responsiveness ofthe C3H/HeJ mice (10) . It is now appreciated that macrophages are induced by LPS to release a number of products that participate in the mediation of injury (1 1), including the monokine termed tumor necrosis factor (TNF)/cachectin (12, 13) .
The potential of TNF as a mediator of endotoxin-induced injury was first considered when Beutler et al. isolated the macrophage product termed cachectin, and amino acid sequencing and bioassays confirmed the identity of cachectin and TNF (14) . These studies were extended to show that pretreatment of mice with anticachectin antiserum provided a modest protection from the lethal effects of endotoxin (15) . Moreover, infusion of recombinant TNF/cachectin into rats, dogs, and mice induces a number ofpathophysiologic changes not unlike those observed in septic shock (16) (17) (18) . Unfortunately, there have been no studies to date using well established animal models of endotoxic shock performed with highly purified preparations of LPS where TNF levels in the blood are quantitated, correlated with physiologic changes, and the effect of passive administration of anti-TNF antibodies on LPS-induced injury evaluated. This study attempts to bridge this gap. Herein we describe the isolation and characterization of rabbit macrophage-derived TNF, the dose dependency of LPS-induced TNF production in rabbits using two different forms of Salmonella Minnesota Re595 LPS, namely parent LPS and LPS-HDL complexes and a kinetic modeling analysis that describes TNF production and release into the blood. In addition, experiments are described that provide evidence for an important role of TNF as a mediator of LPS-induced injury since pretreatment of rabbits with anti-TNF antibody significantly protects rabbits from LPS-induced injury and death.
Methods
Animals. Outbred New Zealand White rabbits, male, 1.5-2.5 kg purchased from a commercial supplier were maintained on a standard pelleted diet for 7-14 d before use. Nubian strain goats (70 kg) were utilized for antibody production.
LPS. S. minnesota ReS95 bacteria were obtained from A. Nowotny (University of Pennsylvania, Philadelphia) and grown in 550 1 fermenters using a 0.1 Mphosphate-buffered medium containing 2.25% yeast extract, 1.1% peptone, and 1% cerelose (baker's glucose). The bacteria were harvested at late log phase growth, washed in distilled water, and lyophilized. LPS was extracted from the bacteria using the phenol-chloroform-petroleum ether (PCP) method of Galanos (19) . After the final ether wash, the dried LPS was suspended in 20 mM EDTA, pH 7.5, to a final concentration of 10 mg/ml and sonicated (four 20-30-s bursts at 50% output using a model W-375 sonicator; Heat Systems-Ultrasonics, Inc., Plainview, NY) until the solution was clarified. The LPS solution was dialyzed against sterile distilled water (six changes over 3 d) and lyophilized. Stock solutions of the LPS (5 mg/ml) were prepared by sonication in 20mM EDTA, pH 7.5. LPS for use in tissue culture was dialyzed against sterile saline until free of EDTA, followed by determination of the final concentration of LPS using an assay for keto-deoxyoctulosonate (20) . Parent LPS for in vivo studies was prepared by diluting the stock LPS in sterile saline as required for a l-ml injection. Plasma-altered LPS (PA-LPS) for injection was prepared by incubating parent LPS (0.5 mg/ml final concentration) in 10 mM EDTA anticoagulated isologous platelet free plasma for 30 min at 370C followed by dilution with an equal volume ofsterile saline. Partially purified LPS-HDL complexes were prepared by adding 2.1 g solid cesium chloride to 5 ml freshly prepared PA-LPS followed by centrifugation for 60 was made, followed by aseptic lavage of the perito~neum with 500 ml ice-cold RPMI 1640 supplemented with 2 mM L-glutamine, 1 mM Na pyruvate, 50 U/50 ,ug penicillin/streptomycin per ml, 10 mM Hepes, 2% fetal bovine serum, and 5 U/ml heparin. The harvested cells were centrifuged (1,000 g, 10 min 4C) and resuspended in the above medium without FBS (serum-free medium). After an additional spin and resuspension in serum-free medium, the cells were counted using a hemocytometer and plated in 150 cm2 flasks at a density of 8-10 X I0O macrophages/flask. After 2 h at 37°C, 5% CO2, nonadherent cells were removed from the flasks by vigorous washing and replenishment with 20 ml serum-free medium. The mineral oil induced peritoneal exudate cells, when examined using Wright's stained cytocentrifuge preparations, contained -60% macrophages, 35% neutrophils, and 5% lymphocytes. After plating and washing, the adherent cells were > 90% macrophages. TNF-containing conditioned medium was generated by incubating the macrophage cultures overnight in the presence of0.1 Mg Re595 LPS/ml, and the conditioned medium was centrifuged 2,000 g, 30 min, and stored at -20°C.
To determine the response ofPEM to the LPS preparations used in these studies, PEM were plated in six-well clusters (3.5 cm wells, 5 X 106 PEM/well, 1.25 ml serum-free medium) and after washing and replenishment of medium, parent LPS, PA-LPS or LPS-HDL was added over the LPS dose-response range, 10 pg/ml to 1 ,ug/ml. After 18 h the conditioned medium was centrifuged and tested for TNF (cytolytic) activity. As shown in Fig. 1 , TNF was maximally induced by 1-10 ng/ml parent LPS, whereas 0.1-1 g/ml PA-LPS or LPS-HDL was required for maximal induction.
Purification of rabbit TNF from conditioned medium of LPStreated PEM. TNF containing PEM supernatants were pooled to yield 3 liters, and the following additions were made: (final concentration) 10 mM EDTA, 0.05% octyl O-D glucopyranoside (00; Calbiochem, La Jolla, CA) and 0.5 M NaCI, followed by application to a DEAE cellulose column (2.25 X 15 cm, Amicon Matrix Cellufine AM; Amicon Corp., Danvers, MA). The flow-through material was concentrated 75-fold using a 10,000 mol wt cut-off filter (Millipore PTGC), and diafiltration was performed using 20 mM Tris-buffered 0.05% OG, pH 7.5 until the conductivity was below 2 mMho. OG was added (0.5% final concentration) to maximize recovery of TNF, and the material was applied to a Fractogel TSK DEAE-650s (EM Science, Gibbstown, NJ) column (2.5 X 6 cm) using a 50-ml superloop (Pharmacia Fine Chemicals, Piscataway, NJ) with a series 4 HPLC (Perkin-Elmer Corp., Norwalk, CT) (Fig. 2) . After the flow-through peak was collected, the bound proteins were eluted with a linear gradient (0-0.25 M NaCI). The fractions (7.5 ml/fraction) containing cytolytic activity were LPS. Adherent rabbit PEM were incubated overnight with parent LPS, PA-LPS or partially purified LPS-HDL as described in Methods, followed by measurement of TNF activity in the conditioned medium using the L929 cytolytic assay. (28) , and after centrifugation (10 mmn, 700 g) and aspiration of the plateletrich plasma, the red cells were washed three times by centrifugation (5 min, 2,000 g) and resuspension in 10 mM Hepes saline, pH 7. 1 vol of packed cells was suspended in 9 vol of goat serum, and after 10 min with gentle mixing at 00C, the cells were pelleted (5 min, 2,000 g) and the serum was harvested. Globulin fraction was prepared by mixing equal volumes of the adsorbed serum with saturated ammonium sulphate (Ultrapure grade; Schwartz/Mann Biotech, Cleveland, OH), pH 7, for 2 h, 00C followed by centrifugation (2,000 g, 30 min) and solubilization of the precipitate in 10 mM Hepes saline, pH 7. After two additional precipitations, the globulin fraction was dialyzed aganst 10 mM Hepes saline, pH 7, for 24 h, exposed to 1 mM diisopropylfluorophosphate (DFP) for 30 min at room temperature and further dialyzed against five changes of Hepes saline over 60 h. The final protein concentration was 42 mg/ml for the anti-TNF globulin and 31 mg/ml for the NGG.
The neutralizing capacity of the antibody was determined by mixing equal volumes of HrTNF or PEM-TNF (1-2 X 103 U/ml) with various dilutions ofthe antiserum or globulin fraction. After 60 min at 370C, the mixtures were tested for residual cytolytic activity in the L929 assay. As shown in Fig. 4 recovered with an apparent 150,000 mol wt. In preliminary in vivo experiments we found that the cytolytic activity (2-3 X 103 U/mi) of serum which was collected 50-100 min after injection of 10 ,g Re595 LPS was neutralized > 95% after incubation (60 min at 370C) with 10-fold diluted goat anti-HrTNF globulin. Moreover, infusion of 2-4 ml i.v. of the globulin fraction ofanti-TNF was sufficient to neutralize (> 95%) the serum cytolytic activity which appeared 45-100 min after injection of 10 Mg i.v. parent LPS (data not shown).
To rule out the possibility that the goat anti-TNF antiserum contained antibodies specific for Re595 LPS, we tested preimmune, immune, and control goat serum and globulin fractions using an enzyme-linked immunoassay that could detect as little as I ng antiRe595 and were unable to detect specific antibody in any of the samples, indicating that immunization of the goats with HrTNF did not induce an anti-LPS response.
Importantly, when tested in a chromogenic Limulus Assay (Whittaker M.A. Bioproducts, Walkersville, MD) endotoxin contamination was observed to be < 0.5 ng/ml. Moreover, injection of 8 ml i.v. ofthe globulin fraction did not induce significant elevation of core temperature in rabbits (< 0.4°C increase), although transient leukopehia (40-60% decrease in WBC levels) was observed (5-15 min) postinjection with recovery to normal WBC levels by 30 min.
In vivo studies. Rabbits were fasted overnight to achieve normalization of the nutritional status. At 7 a.m. the following morning, the rabbits were briefly secured in the supine position, and a femoral artery cannula was placed to the level of the lower abdominal aorta using local anesthesia (2 ml 1% procaine; Breon Laboratories, Inc., New York). The surgical wound was sutured, and the rabbits were placed in restraining suits (Torso Sling Suits; Alice King Chattam, Los Angeles, CA) that permitted the animals to stand or recline in the prone position without disrupting experimental procedures (injections, blood collection, and monitoring of mean arterial pressure and core temperature). After baseline parameters were established, saline, NGG, or anti-TNF globulin was infused (routinely 8 ml injected through the marginal ear vein over 4 HrTNF antiserum or rat anti-PEM-TNF antiserum) followed by incubation at 37°C for 60 min. Residual cytolytic activity was determined using the L929 cell assay as described in Methods. 
Results
As a basis for these studies we first determined conditions for optimal production of TNF in vitro by rabbit PEMs. In addition, a procedure was devised to purify rabbit TNF so that the specific activity and in vivo circulating half-life of the TNF could be determined. As shown in Fig. 1 , TNF is maximally induced in PEM by overnight exposure to 1-10 ng/ml of parent Re595 LPS or 0.1-1 g/ml PA-LPS. When the PEM-TNF was purified to homogeneity by anion exchange chromatography followed by chromatofocusing and gel filtration (Figs. 2 and 3), a specific activity of 1 X 108 U/mg was observed using actinomycin D-treated L929 cells Table I . The majority of IL-I activity in the PEM-conditioned medium, determined using a comitogenic assay with C3H/HeJ mouse thymocytes as described by Scala and Oppenheim (30) , was eluted from the DEAE column early in the salt gradient (fraction 24 tibody, a finding consistent with published reports that IL-I has cytolytic activity (31) . These data indicate that the specific activity of rabbit TNF is 5-10-fold greater than that observed for purified human recombinant TNF. Comparable specific activities were suggested for purified HL60-derived TNF (32) .
Induction ofTNF in vivo by plasma-altered LPS in rabbits.
We and others have shown previously that exposure of LPS to serum or plasma results in formation of LPS-HDL complexes (5, (33) (34) (35) . Moreover, evidence has been presented suggesting that during gram negative sepsis LPS-HDL complexes may form as a consequence of interactions between bacteria and plasma (36) . Because LPS-HDL complexes may play a role in inducing many of the pathologic changes of gram negative sepsis, we performed the following experiments to determine the efficacy of LPS-HDL in inducing TNF in vivo.
Rabbits were cannulated and placed in restraining suits for monitoring of physiologic parameters as described in Methods. After establishment ofbaseline parameters, an intravenous bolus of PA-LPS (PA-LPS, 250, 50, or 10 ,ug of LPS injected) was administered using the marginal ear vein. As shown in Fig. 5 , after injection of 250 ,gg PA-LPS, peak levels of cytolytic activity (2-3 X 103 U/ml) were observed over 45-100 min. Injection of 50 ,g PA-LPS resulted in substantially lower peak levels of TNF (500 U/ml), and after injection of 10 ,g PA-LPS a minimal response (< 250 U/ml) was observed. Cytolytic activity levels decreased over 100-200 min and became undetectable 200 min after injection of LPS. As shown in Fig. 6 However we also considered the possibilities that LPS might induce inhibitors that would: (a) block directly the cy- were mixed with equal volumes of conditioned medium from LPS-treated rabbit PEM, and after a 30-min incubation at 37°C, the mixtures were tested for cytolytic activity. As shown in Table II , good recoveries of PEM supernatant cytolytic activity was observed in all ofthe mixtures, suggesting that inhibitors of TNF cytolytic activity were not present in plasma either before or after LPS injection. Next, aliquots of the same serum samples were added to cultures ofrabbit PEM (1, 5, and 10% final serum concentration) followed by addition ofLPS (1 ,ug/ml), and after 18 h the conditioned medium was tested for TNF activity. As shown in Table III , LPS induction in vitro was not inhibited by serum that was collected either before or after injection of LPS in vivo. Thus, we did not find evidence for a serum inhibitor that would result in unresponsiveness of macrophages (or other TNF-producing cells) to a second dose of LPS in vivo. Finally, to determine if TNF itself could render macrophages hyporesponsive to stimulation by LPS we exposed adherent rabbit PEM to human recombinant TNF over the dose response range 0.01 to 100 ng/ml for 2 h followed by addition of 10 ng Re595 LPS/ml. After 18 h at 37°C the conditioned medium was tested in the L929 cell assay, and no evidence for a direct effect of TNF on LPS-induced TNF production was Fig. 9 , when rabbits were pretreated with 10 1g parent Re595 LPS at t = 0 followed by injection of DEAE-purified PEM-TNF at t = 200 min, the disappearance kinetics Fig. 8 . t PEM were cultured in 6-well clusters in serum-free medium as described in Methods, and pooled serum samples (n = 4) from each time point were added to achieve a final concentration of 10, 5, or 1%, followed by addition of parent Re595 LPS (1 ug/ml final concentration). § TNF activity was below background (< 30 U/ml) in wells that re- . Disappearance of rabbit macrophage-derived TNF from plasma after intravenous injection in either normal or LPS pretreated rabbits. Femoral artery cannulation was performed to facilitate collection of blood samples and the rabbits were placed in restraining suits as described in Methods. After injection of TNF (either "5I-TNF or unlabeled TNF) blood samples were collected and analyzed for residual counts per minute using a gamma counter, or for residual TNF activity using the L929 cytolytic assay.
were comparable to those of control rabbits that did not receive LPS. Because inhibitors of TNF cytolytic activity were not detected in serum samples collected either before or after injection of LPS, we felt that by incorporating the observed parameters into a mathematical model of the LPS-induced TNF release, we would obtain a reasonable approximation of the total amount of TNF released into the plasma compartment. Accordingly, we constructed a model consisting of the following: The rate constant k was set to 1 min' in accordance with the observed t/2 of the fast component (e.g., k = In 2/t1/2; t112 = 0.5-1 min). The dependent variable, v (velocity of TNF release from compartment 1 into compartment 2, expressed as U/min) was optimized at 1-min intervals over t = 30 min to 200 min to yield TNF levels in compartment 2 that would agree with observed TNF levels in serum (Fig. 5) . Following optimization of the incremental velocities over t = 30 to 200 min, numerical integration was performed to determine the total amount of product released into compartment 2. As shown in Fig. 10 , the total amount of TNF transferred from compartment 1 to compartment 2 was calculated to be 2.2 X 107 U (220 ,g, TNF). Recalculation of the model using the slow clearance rate (t1/2 = 11 min) suggested an absolute minimal estimate of TNF release of 8 Mg. On the basis of(a) extrapolation ofthe slow component ofthe disappearance curve ( Figure 10 . Kinetic model of TNF release and disappearance from plasma after intravenous injection of LPS in rabbits. In this computer simulation, TNF was released from compartment 1 (source) at the required velocity (U/min) to achieve plasma (compartment 2) levels consistent with experimentally observed values. The rate constant (k2) for clearance of TNF from compartment 2 was set to 1 min-' in accordance with the experimentally observed values for t,,2 fast (Fig. 9) . The TNF levels in compartment 2 are based on the observed plasma volume for 2-kg rabbits.
which further challenge with LPS induced no detectable TNF in the serum. To examine the possibility that TNF could mediate the hyporesponsive state the following experiment was performed. After placement of femoral artery and venous catheters, rabbits were put into restraining suits and HrTNF (< 0.1 ng endotoxin/mg) was administered through the femoral vein cannula using an infusion pump that was programmed to deliver 200 ,g TNF over 30-150 min in proportion to the in vivo release velocities predicted by the model illustrated in Fig.  10 . As shown in Fig. 1 , serum TNF levels of 1 X 104 U/ml were observed over 60-100 min followed by return toward baseline levels by 250 min. After injection of 10 ,g i.v. parent LPS (300 min) using the marginal ear vein, a second peak of cytolytic activity [4] [5] [6] [7] In four of the rabbits, the primary infusion was followed by a second continuous slow infusion of 8 ml beginning at t = 0 and continuing until t = 60 mim. PA-LPS (250 ,g) was administered as a bolus at t = 0 min. As shown in Fig. 12 , peak TNF levels of 2.5-3 X 103 U/ml were observed over 45-100 min in rabbits that were pretreated with NGG. Prior infusion of anti-TNF resulted in > 95% neutralization of the LPS-induced cytolytic activity. Furthermore, additional slow infusion of antibody did not result in more complete neutralization of TNF or provide greater protection from the hypotension changes (data not shown). Persistence ofthe anti-TNF antibody in plasma of control animals and the clearance of antibody from plasma of LPS-treated rabbits is shown in Table IV .
In the NGG-treated rabbits MAP fell 15-20% over 0-75 min and continued to decline over 100-500 min for a total decrease of 40%. In contrast, MAP remained in the normal range in rabbits that were pretreated with anti-TNF. Using the distribution-free analysis of Koziol (29) the differences in MAP between the antibody-and NGG-pretreated rabbits were found to be significant (P = 0.0 14). Both groups of animals, NGG and anti-TNF pretreated, developed leukopenia followed by partial recovery of cell counts to the normal range.
Multiple injections, 10 Mug iv. parent ReS95 LPS. Because 10 ,ig of parent LPS was the smallest dose that resulted in maximal induction of TNF, this dose was selected to examine more closely the protection afforded by infusion of anti-TNF antibody. After cannulation and placement of rabbits in restraining suits, infusions of anti-TNF, NGG or saline (8 ml injection over 4 min using the marginal ear vein) were made 45 min before injection of a 10-Mg bolus of parent LPS. As was administered using the marginal ear vein at t = 0. § On the basis of the titer of the administered anti-TNF (Fig. 4) and the plasma volume of the rabbits (-70 ml) an initial titer of nine was expected. II Titer not determined.
shown in Fig. 13 serum TNF levels of 2-3 X 103 U/ml were observed over 60-100 min in the saline and NGG pretreated rabbits, and MAP were decreased 30-40% over 500 min. In contrast, serum TNF levels of anti-TNF pretreated rabbits were below the threshold of the assay, and MAP remained within the lower limits of the normal range (P = 0.021). As shown in Table IV at t = -45 min. LPS (10 gg in 1 ml i.v. saline) was injected at t = 0, 300 min, and 24 h. levels and core temperatures were not significantly different between the three groups. The second dose of LPS (t = 300 min) did not induce detectable levels of TNF, and the hypotensive change was not significantly accelerated. At the conclusion of the 500-min monitoring period the surgical wounds were sutured, and the rabbits were returned to cages for overnight observation. Animals recognized as being moribund (e.g., MAP < 55 mmHg and CT < 36QC) were killed by injection of sodium pentobarbital, and autopsies were performed. At t = 24 h, monitoring of MAP and CT was resumed, and a final injection of 10 gg parent LPS was made. As shown in Table V , 5/5 of the anti-TNF treated rabbits survived > 24 h, whereas none of the animals in the NGG-and saline-pretreated groups survived 24 h. Examination of fixed-tissues at the light microscopic level revealed the following patterns of changes in NGG-and saline-pretreated rabbits: (a) focal hepatic necrosis with fibrin deposition in sinusoids, (b) fibrin deposits in glomerular capillaries and focal tubular necrosis, (c) splenic necrosis with fibrin deposits and accumulation of neutrophils, (d) pulmonary changes of varying degree including edema, atelectasis, and fibrin deposition. In contrast, pathologic changes in tissues from anti-TNF treated rabbits were considerably less severe and were limited to: (a) minimal eosinophilic deposits in Kupffer cells of the liver, (b) occasional protein casts in renal tubules, (c) mild edema and proteinacious deposits in splenic sinusoids, and (d) pulmonary edema and atelectasis. Assessment of fibrin deposition and tissue necrosis changes observed in liver and kidney for the three groups are summarized in Table VI .
Discussion
We have examined the role of TNF as a mediator of LPS-induced injury in a rabbit model of endotoxic shock. TNF is rapidly induced in vivo after intravenous injection of two different forms of LPS: either parent Re595 LPS or PA-LPS (LPS-HDL complexes). Using a kinetic model based on the observed t/2 for purified rabbit TNF and peak levels of LPSinduced cytolytic activity in vivo, we estimated that -130 Mg h at 370C, 5% C02) the RAW cell-conditioned medium generally contains fivefold greater cytolytic activity than the PEM conditioned medium (data not shown). Using the specific activity determined in the present studies for rabbit PEM TNF (1 X 108 U/mg) and the observed TNF titers of conditioned medium from LPS-treated PEM (-1.5 X 103 U/ml) we estimate a maximum TNF concentration of 15 ng/ml. This represents -0.1% ofthe total protein released. Comparable TNF protein levels (-10 ng TNF per ml, corresponding to 0.02% of the total protein released) were observed in conditioned medium from 4B-phorbol 12-myristate 13-acetate-treated HL-60 cells (32) . While TNF may be a major secretory product of some transformed lines such as RAW 264.7 it is not appropriate to assume this conclusion holds for all other macrophage sources.
Production and clearance of TNF in vivo. In order to estimate the amount of TNF released into plasma over the 30-200-min period after injection of LPS, we employed a kinetic model based on: (a) the observed peak TNF levels (-2.5 X 103 U/ml, corresponding to 1.4 nM) observed after injection of LPS and (b) the observed disappearance rates of purified rabbit TNF (t1/2 fast component = 0.5-1 m, t1/2 slow component = 11 min). When the incremental velocity ofTNF release into the plasma compartment was optimized to yield computed plasma TNF levels consistent with experimentally observed values, we obtained a calculated value of 1.3 X 107 U (corresponding to 130 ug) TNF released over the 30-200-min period (based on the plasma volume of a 2-kg rabbit). The observed biphasic disappearance (Fig. 9) suggests that two forms of TNF are cleared from plasma, perhaps depending on the degree of aggregation (40, 41) . Another possibility is that the slow component represents TNF in equilibrium between plasma and receptors (e.g., on endothelium and leukocytes). However, because a significant proportion ofthe TNF released would be rapidly and irreversibly bound to receptors it is possible that this calculated value represents an underestimate of the total amount actually released.
The measurements of serum TNF represented here are consistent with reports from other laboratories although the animal models used differ. For example, Ruff and Gifford observed TNF levels of 7.5 X 103 U/ml in serum from BCG pretreated rabbits that were bled 90 min after an injection of 100 ,g i.v. LPS (42) . Haranaka et al. purified TNF from serum collected 90 min after injection of 100 Mg E. coli 01 1 1 :B4 LPS in P. acnes primed rabbits (25) . On the basis of the specific activity of the purified TNF, the TNF concentration in the starting material serum was 225 ng/ml (12.5 nM). Beutler et al. observed cachectin/TNF levels in the nanomolar range 2 h after injection of LPS in unprimed rabbits (43) .
The half-life of TNF determined in our studies is in the range reported for a number of different cytokines including TNF (43) (44) (45) (46) (47) . Our studies demonstrate good agreement between tNF clearance data obtained by radioisotope tracer measurements and by measurements ofTNF cytolytic activity (Fig. 9) (39) .
We considered the possibility that the TNF released by macrophages could act in an autocrine manner to induce LPS-hyporesponsiveness, thus preventing further TNF release upon subsequent challenge by LPS. However, two lines of evidence from our studies suggest that TNF is not responsible for the hyporesponsive state. First, pretreatment of rabbits with HrTNF did not diminish the endogenous LPS-induced TNF response. As shown in Fig. 11 , when HrTNF was infused in quantities (200 Mig) and rates to approximate as closely as possible in vivo release that would be induced following maximal stimulation by LPS, subsequent injection of 10 Mg parent LPS resulted in appearance of TNF activity in serum with normal kinetics and peak titers (4-7 X 103 U/ml) that were increased approximately twofold over the normally observed levels. When LPS challenge was given 24 h after the HrTNF infusion, the resulting TNF levels (2-3 X 103 U/ml) were comparable to those observed in normal rabbits that received LPS. A second, though indirect line ofevidence suggesting that TNF itself does not mediate hyporesponsiveness to LPS is derived from the anti-TNF pretreatment studies. As shown in Fig. 13 and Table IV , anti-TNF globulin pretreatment resulted in neutralization of LPS-induced serum TNF activity, and in addition, the administered antibody was substantially depleted from the serum. A second injection of LPS failed to induce detectable serum TNF levels or lead to further reduction ofthe anti-TNF titers in serum. Thus, in these animals hyporesponsiveness was induced by LPS in the absence ofdetectable levels of serum TNF. Further studies to elucidate the mechanisms of the hyporesponsive state are under way in our laboratory.
Role of TNF in the mediation ofLPS-induced injury. The work described here provides the basis for continued studies to unravel the mechanism(s) of TNF action and therefore the mechanism(s) of LPS induced injury. We have used rabbits that have not received any systemic anesthesia, are responsive to relatively low concentrations of a highly purified, well characterized LPS preparation and are protected by passive administration of a globulin fraction of anti-TNF serum. Importantly, this antibody was prepared against recombinant human TNF so that antibodies to other monokines would not be present.3 Both the protective and control globulin fractions have been shown to be free of contamination by endotoxin, the presence of which could confound interpretation ofexperimental data.
The pathophysiologic changes observed after bolus injection of 10 ,g i.v. parent Re595 LPS include: (a) hypotensive responses characterized by decrease in MAP 45-100 min after injection of LPS followed by further decline in MAP over 100-500 min, (b) fibrin deposition (primarily in renal glomeruli) and focal hepatic necrosis with increased numbers of marginated PMN in capillaries and sinusoids of the tissues examined, and (c) death within 12 h ofinjection of LPS. In previous studies we have provided evidence that these changes do not require complement activation (48, 50-52). Moreover, other mediators derived from multiple sources have been considered (1) but no single mediator has been identified as being a major element in the initiation of LPS-induced injury.
In the present study, pretreatment with anti-TNF antibody resulted in elimination of the TNF observed in the serum during the 30-200-min period post-LPS. Associated with this neutralization of TNF is reduction of LPS-induced hypotension, abrogation offocal hepatic necrosis and fibrin deposition in liver and kidneys and prevention of lethality. The release of TNF into the blood during the period 30-200 min post-LPS appears to be essential for the evolution of injury since pretreatment with anti-TNF globulin markedly blunts LPS-induced injury while administration ofanti-TNF globulin at 215 min post-LPS does not reverse any of the pathophysiologic changes (data not shown). These data support the concept that TNF is a primary mediator of LPS-induced injury initiating changes that lead to a diverse spectrum of cellular injury. Infusion of HrTNF resulted in fever without alterations of MAP or WBC levels ( Fig. 1 1) , suggesting that circulating TNF alone, in the absence ofadditional factors, does not mediate all ofthe pathophysiologic changes that are induced by LPS. Thus the initial production ofTNF is necessary, though not sufficient to lead to full development of injury, and may act by sensitizing the host to the action of other mediators induced by LPS or through potential autocrine effects of TNF itself (53-55).
Critical issues that remain unresolved are the identity of the cellular targets of TNF in vivo and the mechanism(s) by which TNF alters cell phenotype to lead to injury. A number of recent studies have provided evidence that interactions between TNF endothelial cells and neutrophils (56-67) could produce changes that are relevant to many LPS-induced pathophysiologic changes. Binding ofTNF to neutrophils results in enhanced adherence of the PMN to endothelial cells (58) (59) (60) , inhibition of migration (56) , stimulation of respiratory burst and degranulation (61, 62) . In addition, Shalaby et al. observed disruption of endothelial cell monolayers in vitro by TNF treated PMN (56) . Interaction of TNF with endothelial cells has been shown to result in: (a) reorganization (elongation, overlapping of cells, rearrangement of actin filaments and loss of stainable fibronectin matrix) (63) (b) expression of tissue factor-like procoagulant activity (64, 65) (c) diminished expression of thrombomodulin activity (64), (d) increased expression of plasminogen activator inhibitor (PAI-1) (66, 67) and (e) adherence of PMN to endothelial cells (58, 59 ). In addition, van Hinsbergh et al. observed increased plasma PAI in rats 2 h after a bolus injection of 2.5 X lI0 U TNF/kg (equivalent to -10 ,ug TNF/kg) (67). Finally, Remick et al. (18) reported endothelial cytoplasmic blebbing and gap formation between endothelial cells in mice 2 h after injection of TNF (50 gg HrTNF/kg). Recently, in studies of the mechanisms of TNF action, Kettlehut et al. provided evidence that cyclooxygenase inhibitors provided protection from rapid killing, eventual lethality and other pathophysiological changes that were induced by injection of human recombinant TNF (4 mg/kg i.v.) in rats (68). Altogether these findings suggest a number of mechanisms for LPS-induced pathophysiologic changes; nevertheless, it is likely that further elements of the injury pathways remain to be considered. For example, could hypotensive changes be mediated in part by endothelium-derived relaxing factors induced in endothelial cells, either directly by LPS or indirectly by TNF, IL-1 or other cytokines (69) .
Whether TNF participates as a primary mediator of injury during gram-negative septicemia in man is at present unknown. Results from recent clinical studies suggest that detectable TNF levels in septic patients are considerably lower than the nanomolar levels induced in experimental animals by infusion of purified LPS or bacteria. For example, Wage et al. (70) used a cytolytic assay (WEHI 164 clone 13 cells) to measure TNF levels in sera from 79 patients with menningoccal disease and found that the majority, (61/79) were below the detection limit of the assay (< 2 pg/ml). TNF levels in the remaining samples ranged in general from 2 to 300 pg/ml, and all of the patients (5/79) with TNF levels > 0.1 ng/ml died (70) . In an earlier study, 3/23 septic patients were found to have TNF levels of 3-20 pg/ml (71) . Tracy et al. employed a skeletal muscle depolarization assay to detect picomolar levels of TNF in plasma samples of critically ill patients (72, 73) . Using an ELISA with a sensitivity of 39 pg TNF/ml, Scuderi et al. observed that TNF levels were frequently elevated in patients with kala-azar or malaria (67 and 70%, respectively; geometric mean 1 9 pg/ml) (74). However in view ofthe rapid and apparently evanescent release ofTNF in animals it may be difficult to detect elevated levels of TNF in serum in patients where initial exposure to an inducer such as LPS occurred prior to clinical observation. Nevertheless, the studies described here document a central role for TNF in mediating endotoxin-induced injury, support and extend the observations of others (15) (16) (17) (18) 68 
